PD-L1/2: PROGNOSTIC SIGNIFICANCE IN ONCOLOGY
Keywords:
solid malignant tumors, lymphoproliferative diseases, immune control points, PD-1, PD-L1/2, prognostic factors, programmed cell death, T-lymphocytes.Abstract
Summary. Purpose of the review: analysis of up-to-date
information on the predictive value of the expression of
PD-L1/2 proteins (programmed death ligand) on cells
of malignant neoplasms (MN) of different histogenesis
and localization. Most studies indicate an unfavorable
prognostic role of PD-L1/2 expression in MN of epithelial origin, melanoma, sarcoma, and oncohematological diseases (although the latter have been less explored
in this regard). This is illustrated by worse survival rates
of patients, features of the histostructure of the tumor,
and the widespread stages detected with hyperexpression
of these molecules. Continuing research on this marker may contribute to further progress in understanding
the pathogenesis of MN and accelerate the development
of innovative therapeutic options.
References
Dolan DE, Gupta S. PD-1 pathway inhibitors: changing
the landscape of cancer immunotherapy. Cancer Contro 2014;
(3): 231–7.
Riley JL. PD-1 signaling in primary T cells. J Immunol rev
; 229: 114–25.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression
of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11 (11): 3887–95.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and
its ligands in tolerance and immunity. Annu Rev Immunol 2008;
: 677–704.
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5 (12): 1365–69.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the
PD-1 immunoinhibitory receptor by a novel B7 family member
leads to negative regulation of lymphocyte activation. J Exp Med
; 192 (7): 1027–34.
Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J
Exp Med 2001; 193 (7): 839–46.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol
; 2 (3): 261–68.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated
B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (8): 793–800.
Topalian SL, Sznol M, Mcdermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32
(10): 1020–30.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to
Hodgkin lymphoma. J Exp Med 2003; 198 (6): 851–62.
Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1
on tumor cells in the escape from host immune system and tumor
immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA
; 99 (19): 12293–97.
Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111 (7): 3635–43.
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/
B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr
Opin Immunol 2012; 24 (2): 207–12.
Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PDL1, IDO, and T(regs) in the melanoma tumor microenvironment is
driven by CD8(+) T cells. Sci Transl Med 2013; 5 (200): 200ra116.
Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13 (1): 84–8.
Gao Q, Wang X-Y, Qiu S-J, et al. Overexpression of PD-L1
significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer
Res 2009; 15 (3): 971–9.
Guo W, Wang P, Li N, et al. Prognostic value of PD-L1 in
esophageal squamous cell carcinoma: a meta-analysis. Oncotarget 2017; 9 (17): 13920–33.
Zhuan-Sun Y, Huang F, Feng M, et al. Prognostic value of
PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 2017; 10: 5005–12.
Zhang M, Dong Y, Liu H, et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric
cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep
; 6: 37933.
Yang C-Y, Lin M-W, Chang Y-L, et al. Programmed cell
death-ligand 1 expression in surgically resected stage I pulmonary
adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50 (7): 1361–9.
Jong-Mu Sun, Wei Zhou, Yoon-La Choi. PD-L1 expression and survival in patients with non-small cell lung cancer in Korea. J Clin Oncol 2014; 32 (5): 8066.
Sun JM, Zhou W, Choi YL, et al. Prognostic significance of
PD-L1 in patients with non-small cell lung cancer: a large cohort study
of surgically resected cases. J Thorac Oncol 2016; 11 (7): 1003–11.
Hidefumi S, Tsutomu T, Katsuhiro O, et al. PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small
cell lung cancer. Mol Clin Oncol 2014; 2 (6): 1035–42.
Hino R. Tumor cell expression of programmed cell death-1
ligand 1 is a prognostic factor for malignant melanoma. Cancer
; 116 (7): 1757–66.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity,
and immune correlates of anti-PD-1 antibody in cancer. N Engl J
Med 2012; 366 (26): 2443–54.
Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with
nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol
; 31 (suppl): 3016.
Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1
expression in renal cell carcinoma. A systematic review and metaanalysis. Target Oncol 2016; 11 (2): 143–8.
Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in
breast cancer: a meta-analysis. BMC Cancer 2017; 17 (1): 690.
Müller T, Braun M, Dietrich D, et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget 2017; 8 (32): 52889–900.
Aghajani M, Graham S, McCafferty C, et al. The clinicopathological and prognostic significance of programmed cell
death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis. Thyroid 2018; 28 (3): 349–61.
Zhang Y, Kang S, Shen J, et al. Prognostic significance of
programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1). Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 2015; 94 (6): e515.
Zhu Z, Jin Z, Zhang M, et al. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Oncotarget
; 8 (35): 59570–80.
Rosenwald A, Wright G, Leroy K. Molecular diagnosis of
primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. JEM 2003; 198 (6): 851.
Kim C, Kim EK, Jung H, et al. Prognostic implications of
PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 2016; 16: 434.
Liu YX, Wang XS, Wang YF, et al. Prognostic significance
of PD-L1 expression in patients with gastric cancer in East Asia:
a meta-analysis. Onco Targets Ther 2016; 9: 2649–54.
Dai C, Wang M, Lu J, et al. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer:
a meta-analysis. Onco Targets Ther 2017; 10: 3625–34.
Li J, Wang P, Xu Y. Prognostic value of programmed cell
death ligand 1 expression in patients with head and neck cancer:
A systematic review and meta-analysis. PLoS One 2017; 12 (6):
e0179536.
Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in
solid tumor: An updated meta-analysis. Medicine (Baltimore)
; 96 (18): e6369.
Bellmunt J, Mullane SA, Werner L, et al. Association of
PD-L1 expression on tumor-infiltrating mononuclear cells and
overall survival in patients with urothelial carcinoma. Ann Oncol
; 26 (4): 812–7.
Vital D, Holzmann D, Huber GF, et al. PD-L1 is a positive
prognostic factor in squamous cell carcinoma of the nasal vestibule. Rhinology 2018. doi: 10.4193/Rhin17.215.
Boussiotis VA. Cell-specific PD-L1 expression in DLBCL.
Blood 2015; 126 (19): 2171–2.
Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015;
(19): 2193–201.
Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on
neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 2016; 128
(10): 1374–81.
Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression
in Hodgkin and B-cell lymphomas. Hum Pathol 2016; 54: 17–24.
Svergun N, Khranovska N, Kriachok I, et al. The role of
microenvironment expression of PD-1 ligands and chemokines
in clinical outcome of hodgkin’s lymphoma. Ann Oncol 2014; 25
(4): iv329.
